We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?
Read MoreHide Full Article
McKesson Corporation (MCK - Free Report) is scheduled to release third-quarter fiscal 2018 results on Feb 1, before the market opens.
Last quarter, earnings of $3.28 per share beat the Zacks Consensus Estimate of $2.78. In the trailing four quarters, McKesson's earnings beat the same with the average being 4.9%.
Meanwhile, the Zacks Consensus Estimate for revenues for the third quarter is pegged at $52 billion, which improved 3.7% year over year. Let’s see how things are shaping up prior to this announcement.
Why a Likely Positive Surprise?
Our proven model shows that McKesson is likely to beat estimates because it has the perfect combination of two key ingredients.
Zacks ESP: The company has an Earnings ESP of +0.16%. A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: McKesson currently carries a Zacks Rank #2 (Buy). Note that stocks with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) have a significantly higher chance of beating earnings estimates.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
McKesson Specialty Health unit is likely to drive the company’s top line in the third quarter. The unit is likely to benefit from the closing of the intraFUSION acquisition and the recent BDI Pharma buyout.
The company expects to witness solid performance in its Canadian business in the third quarter. Last quarter, McKesson Canada closed the Uniprix banner acquisition and strengthened independent pharmacies. Per management, Uniprix integration activities are progressing well.
Further, McKesson Prescription Technology Solutions business continues to make progress on the CoverMyMeds integration.
Coming to the Technology Solutions segment, the company divested its Enterprise Information Solutions or EIS business, recently. This marks another important step in the strategic shift to realign the company’s business focus on Distribution Solutions, following the creation of Change Healthcare earlier this year.
McKesson’s strong guidance for fiscal 2018 looks encouraging. The upside is expected to be driven by market growth, acquisitions and divestitures. McKesson expects GAAP earnings per share in the range of $4.80-$6.90 for the fiscal year ending Mar 31, 2018. Adjusted earnings for the same are expected in the range of $11.80-$12.50.
Recently, McKesson announced that it has entered into an agreement to buy RxCrossroads from CVS Health for $735 million.
Other Stocks to Consider
Here are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
Luminex has an Earnings ESP of +14.29% and a Zacks Rank #3.
The Cooper Companies (COO - Free Report) has an Earnings ESP of +10.75% and a Zacks Rank #3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Mckesson (MCK) to Report Q3 Earnings: A Beat in the Cards?
McKesson Corporation (MCK - Free Report) is scheduled to release third-quarter fiscal 2018 results on Feb 1, before the market opens.
Last quarter, earnings of $3.28 per share beat the Zacks Consensus Estimate of $2.78. In the trailing four quarters, McKesson's earnings beat the same with the average being 4.9%.
Meanwhile, the Zacks Consensus Estimate for revenues for the third quarter is pegged at $52 billion, which improved 3.7% year over year. Let’s see how things are shaping up prior to this announcement.
Why a Likely Positive Surprise?
Our proven model shows that McKesson is likely to beat estimates because it has the perfect combination of two key ingredients.
Zacks ESP: The company has an Earnings ESP of +0.16%. A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: McKesson currently carries a Zacks Rank #2 (Buy). Note that stocks with a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) have a significantly higher chance of beating earnings estimates.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
McKesson Corporation Price and Consensus
McKesson Corporation Price and Consensus | McKesson Corporation Quote
What’s Driving the Better-Than-Expected Earnings?
McKesson Specialty Health unit is likely to drive the company’s top line in the third quarter. The unit is likely to benefit from the closing of the intraFUSION acquisition and the recent BDI Pharma buyout.
The company expects to witness solid performance in its Canadian business in the third quarter. Last quarter, McKesson Canada closed the Uniprix banner acquisition and strengthened independent pharmacies. Per management, Uniprix integration activities are progressing well.
Further, McKesson Prescription Technology Solutions business continues to make progress on the CoverMyMeds integration.
Coming to the Technology Solutions segment, the company divested its Enterprise Information Solutions or EIS business, recently. This marks another important step in the strategic shift to realign the company’s business focus on Distribution Solutions, following the creation of Change Healthcare earlier this year.
McKesson’s strong guidance for fiscal 2018 looks encouraging. The upside is expected to be driven by market growth, acquisitions and divestitures. McKesson expects GAAP earnings per share in the range of $4.80-$6.90 for the fiscal year ending Mar 31, 2018. Adjusted earnings for the same are expected in the range of $11.80-$12.50.
Recently, McKesson announced that it has entered into an agreement to buy RxCrossroads from CVS Health for $735 million.
Other Stocks to Consider
Here are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
Bio-Rad Laboratories (BIO - Free Report) has an Earnings ESP of +4.45% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Luminex has an Earnings ESP of +14.29% and a Zacks Rank #3.
The Cooper Companies (COO - Free Report) has an Earnings ESP of +10.75% and a Zacks Rank #3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>